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Background: Common risk factors for coronary heart disease (CHD) and
abdominal aortic aneurysm (AAA) are mainly male gender, past or current
smoking and older age. But little is known about AAA prevalence in this well-
defined population. The aim of this prospective study was to evaluate the prev-
alence of AAA in patients presenting with an acute coronary syndrome and
coronary stenosis ≥ 50% at coronarography.
Material and methods: Between February 2008 and March 2009, 306
patients hospitalized for an acute coronary syndrome (unstable angina, Q-wave
myocardial infarction or non Q-wave myocardial infarction) gave informed
consent for AAA ultrasound (US) screening. Maximal anteroposterior longitu-
dinal and transverse diameter were measured. AAA was considered if at least
one diameter was equal or exceeded 30 mm. Risk factors for cardio-vascular
disease and coronary status were prospectively collected. Characteristics of
patients with or without AAA were compared using Khi2 or Fisher test as
appropriate if variables were qualitative and using Wilcoxon test if variables
were continuous.
Results: Among 304 patients with reliable US (feasibility 99.4%), preva-
lence of AAA was 6,6% (20/304). Prevalence tended to increase in patients
older than 50 years (p = 0.09). No AAA was detected in patients less than 50
years. Prevalence reached 7,7 % (20/260) in patients > 50 years, 7.4 % (13/
176) in patients > 60 years and 9,6 % (11/114) in patients > 70 years. Previous
coronary events were more frequent in patients with AAA (p = 0.02). In men
older than 50 years, current or past smokers with previous coronary events,
prevalence raised to 13% (8/63).
Conclusion: Prevalence of AAA in patients with acute coronary syndrome
and coronary stenosis ≥ 50% was 6,6% in this study ; furthermore, screening
seemed particularly interesting in men aged more than 50 years, smoker with
personal history of coronary disease, because of a prevalence more than 10%.
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Background: Symptomatic or asymptomatic peripheral artery disease
(PAD) is a strong marker of cardiovascular events and Death. The prevalence
of PAD is well documented in a high-risk subset, but less information is avail-
able in patients with moderate or intermediate CV risk.
Objective: To assess the prevalence of asymptomatic PAD defined as an
ABI≤0.9 in subjects with moderate cardiovascular (CV) risk.
Methods: PANDORA is a multicentre, international, cross-sectional obser-
vational study performed in primary care. ABI measurement was performed in
subjects with > 2 CV risk factors (RF) with no overt vascular disease nor dia-
betes mellitus.
Results: Among 10287 subjects in Europe, 1011 were included in France.
The mean age is 65 yrs (males 55%). ABI≤0.9 was found in 12.2% (95%CI
[10.1;14.2]). Mean LDL-cholesterol was 1.29 g/L. Results for RF association
(Logistic regression) are shown in table 1.
Table. 
Conclusion: In the Pandora study, the prevalence of asymptomatic PAD
among subjects with moderate CV risk in France is 12.2%, strongly related to
smoking and low physical activity. In patients with moderate CV risk, detec-
tion of asymptomatic PAD and management of modifiable RF such as
smoking and physical activity could improve the overall CV risk. PANDORA
Study was sponsored by AstraZeneca.
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Purpose: The beneficial effect of lipid-lowering drugs on cardiovascular
mortality is well established, but long term safety data remain scarce. The aim
of this study was to assess 10-year risk of cancer mortality according to blood
lipid levels and lipid-lowering drug exposure, in the French general popula-
tion.
Methods: Our analysis was based on the Third French MONICA Cross-
sectional survey on cardiovascular risk factors (1995-1996). Participants aged
35-64 years were randomly recruited from French polling lists. Subjects with
a history of cancer at baseline were excluded from the analysis. Vital status
and cause of mortality were obtained 10 years after inclusion.
Results: There were 3262 participants and 177 deaths were recorded (78
due to cancer). The sample was mainly composed of subjects in primary car-
diovascular prevention (96%) and comprised 64% of normolipidemic, 25% of
untreated dyslipidemic (total cholesterol ≥ 6.5 mmol/L or triglycerides ≥ 3.5
mmol/L) and 11% of dyslipidemic subjects treated with a lipid-lowering drug
(4% statin, 6% fibrate). After adjustment for centre, age, smoking, gamma-
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 Chi2 p-value OR 95%CI
Age 0.705 1.004 0.982-1.027
Gender (male vs female) 0.982 1.006 0.600-1.686
BMI 0.325 0.972 0.916-1.029
Family history of premature CHD 
(yes vs no)
0.744 1.133 0.534-2.405
HDL-C (low vs not low) 0.898 1.039 0.577-1.872
LDL-C (High vs not high) 0.427 0.847 0.562-1.276
Sitting BP (hypertension vs normal BP) 0.071 1.598 0.961-2.657
Smoking status (Habitual smoker 
vs non-smoker)
0.012 2.017 1.166-3.489
Physical activity (inactive vs active) 0.0003 2.144 1.414-3.250
Alcohol (high intake vs no intake) 0.845 0.927 0.433-1.984
Statin treatment (Treated vs Untreated) 0.101 0.601 0.329-1.104
